Financing ·
NantWorks exercises warrants for $3.9M in gross proceeds from PDS Biotechnology
PDSBPDS Biotechnology Corp
NantWorks exercised outstanding common stock warrants to purchase an aggregate of 17,699,115 shares of PDS Biotechnology Corporation at an exercise price of $0.22 per share, generating approximately $3.9 million in gross proceeds. The transaction includes pre-funded warrants for the portion that would have exceeded a 19.9% beneficial ownership limitation. PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer.